Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged Catalent (NYSE: CTLT) to develop and manufacture a cGMP-grade psilocybin drug product for: use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and potential wider commercial use.

Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation development and cGMP manufacture of its own psilocybin. Interim results from the PsiGAD trial remain internally confidential to maintain blinding and integrity of the trial, however, a report from the independent data safety monitoring board on the interim results will be released soon, when available.

Incannex …

Full story available on